Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sorich

Showing results (31-40 of 216) with videos related to

Pageof 22
Sort By:
Therapeutic Advances in Medical Oncology|February 14, 2018
Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ studyArduino A Mangoni, Ganessan Kichenadasse, Andrew Rowland, et al.
Breast (Edinburgh, Scotland)|June 7, 2019
Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansineAshley M Hopkins, Andrew Rowland, Jessica M Logan, et al.
Circulation. Cardiovascular Genetics|September 27, 2014
CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysisMichael J Sorich, Andrew Rowland, Ross A McKinnon, et al.
Journal of Chemical Information and Modeling|February 26, 2009
Partial charge calculation method affects CoMFA QSAR prediction accuracyRuchi R Mittal, Lisa Harris, Ross A McKinnon, et al.
Journal of Clinical Medicine|November 6, 2019
Validation and Adaptation of the Multidimensional Prognostic Index in an Older Australian CohortKimberley Bryant, Michael J Sorich, Richard J Woodman, et al.
JNCI Cancer Spectrum|February 22, 2023
Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shiftAshley M Hopkins, Jessica M Logan, Ganessan Kichenadasse, et al.
Frontiers in Oncology|September 12, 2019
Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and DocetaxelAshley M Hopkins, Andrew Rowland, Ross A McKinnon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLCMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Pigment Cell & Melanoma Research|February 14, 2019
Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial dataAshley M Hopkins, Madele Van Dyk, Andrew Rowland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 19, 2019
Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical TrialsMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Pageof 22

Showing results (31-40 of 216) with videos related to

Sort By:
Pageof 22
Therapeutic Advances in Medical Oncology|February 14, 2018
Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ studyArduino A Mangoni, Ganessan Kichenadasse, Andrew Rowland, et al.
Breast (Edinburgh, Scotland)|June 7, 2019
Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansineAshley M Hopkins, Andrew Rowland, Jessica M Logan, et al.
Circulation. Cardiovascular Genetics|September 27, 2014
CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysisMichael J Sorich, Andrew Rowland, Ross A McKinnon, et al.
Journal of Chemical Information and Modeling|February 26, 2009
Partial charge calculation method affects CoMFA QSAR prediction accuracyRuchi R Mittal, Lisa Harris, Ross A McKinnon, et al.
Journal of Clinical Medicine|November 6, 2019
Validation and Adaptation of the Multidimensional Prognostic Index in an Older Australian CohortKimberley Bryant, Michael J Sorich, Richard J Woodman, et al.
JNCI Cancer Spectrum|February 22, 2023
Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shiftAshley M Hopkins, Jessica M Logan, Ganessan Kichenadasse, et al.
Frontiers in Oncology|September 12, 2019
Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and DocetaxelAshley M Hopkins, Andrew Rowland, Ross A McKinnon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLCMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Pigment Cell & Melanoma Research|February 14, 2019
Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial dataAshley M Hopkins, Madele Van Dyk, Andrew Rowland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 19, 2019
Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical TrialsMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Pageof 22